TheraDep Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

TheraDep Technologies is a private, early-stage company developing a proprietary dry-coating platform based on Cold Atmospheric Plasma (CAP) technology. Their BioDep™ process enables the covalent bonding of proteins, peptides, and pharmaceuticals to surfaces like metals, polymers, and ceramics without heat or chemical binders, preserving biomolecule integrity. The company targets four primary verticals: functionalized microplates for assays, coated medical devices, drug-eluting endovascular implants, and scalable coating systems for manufacturing integration. As a platform technology provider, TheraDep is positioned in the high-growth drug delivery and advanced medical coatings sector.

CardiovascularMedical Devices

Technology Platform

BioDep™ process utilizing Cold Atmospheric Plasma (CAP) to covalently bond bioactive molecules (proteins, peptides, pharmaceuticals) to surfaces in a single, dry, room-temperature step without chemical binders.

Opportunities

TheraDep's dry, binder-free coating technology addresses major needs in next-generation drug-eluting devices and high-sensitivity diagnostics.

The platform's material versatility allows it to penetrate multiple multi-billion dollar markets, including advanced medical coatings and life sciences tools, creating multiple potential revenue streams.

Risk Factors

Key risks include the significant technical and regulatory hurdles in scaling the process for GMP manufacturing and obtaining FDA approvals for medical devices.

The company also faces intense competition from established coating methods and must convince conservative device manufacturers to adopt a novel platform.

Competitive Landscape

TheraDep competes with traditional wet-coating chemical suppliers, physical vapor deposition (PVD) and chemical vapor deposition (CVD) equipment makers, and specialized medical coating firms. Its differentiation lies in the dry, low-temperature, covalent bonding process that preserves biomolecule function, but it must displace entrenched technologies and prove cost-effectiveness at scale.

More companies in Drug Delivery & Formulation →More companies in United States →